Hyperglycemia News and Research RSS Feed - Hyperglycemia News and Research

Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Study reveals association between DNA methylation and type 2 diabetes

Study reveals association between DNA methylation and type 2 diabetes

Researchers from the Hospital del Mar Medical Research Institute have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. [More]
American Diabetes Association issues statement to address diabetes management in LTC facilities

American Diabetes Association issues statement to address diabetes management in LTC facilities

The care of adults over age 65 with type 2 diabetes is a growing concern: the prevalence of diabetes is highest in this age group and is expected to grow as the U.S. population ages, with many needing care at long-term care (LTC) facilities. [More]
Lilly receives FDA approval for Humulin R U-500 KwikPen

Lilly receives FDA approval for Humulin R U-500 KwikPen

The U.S. Food and Drug Administration has approved Eli Lilly and Company's Humulin R U-500 KwikPen(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin. [More]
Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

In a study released online today in The BMJ, researchers from Mayo Clinic report a national trend toward overtesting glycated hemoglobin (HbA1C) levels in adult patients with Type 2 diabetes. [More]
T1DM therapeutics market expected to reach $7.1 billion by 2021

T1DM therapeutics market expected to reach $7.1 billion by 2021

Analysis from business intelligence provider GBI Research - Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Gestational diabetes mellitus screening provides more health benefits to pregnant women

Gestational diabetes mellitus screening provides more health benefits to pregnant women

A local research study conducted by KK Women's and Children's Hospital and Duke-NUS Graduate Medical School has found that pregnant patients benefit most from gestational diabetes mellitus (GDM) screening as it allows for timely interventions and brings about health benefits that far outweigh the cost. [More]
Study explores diabetes screening for patients with severe mental illness

Study explores diabetes screening for patients with severe mental illness

A study just published in the Journal of the American Medical Association Internal Medicine examines diabetes screening for patients with severe mental illness, who are two to three times more likely to have type 2 diabetes than the general population. More than seven million Americans in the United States have severe mental illness, and there are many factors contributing to their increased risk of getting diabetes, including treatment with antipsychotic medication. [More]
Pharmacy-led glycemic control program improves outcomes for surgical patients with diabetes

Pharmacy-led glycemic control program improves outcomes for surgical patients with diabetes

A pharmacy-led glycemic control program is linked to improved outcomes for surgical patients with diabetes and those who develop stress-induced hyperglycemia or high blood sugars as a result of surgery, according to a new Kaiser Permanente study published in the American Journal of Pharmacy Benefits. [More]
Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes. [More]
LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older. [More]
Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.35 million federal grant to study how emulsifiers affect bacteria in the intestinal tract and cause chronic inflammatory diseases in the gut. [More]
High blood sugar may reduce positive effects of exercise on bone health in diabetic patients

High blood sugar may reduce positive effects of exercise on bone health in diabetic patients

Diabetes, which now affects almost 30 million Americans, can cause serious health complications, including heart disease, blindness, kidney failure and lower-extremity amputations. [More]
Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Case Western Reserve scientists may have uncovered a molecular mechanism that sets into motion dangerous infection in the feet and hands often occurring with uncontrolled diabetes. It appears that high blood sugar unleashes destructive molecules that interfere with the body's natural infection-control defenses. [More]
Integrated treatment required for diabetes-eating disorder combination

Integrated treatment required for diabetes-eating disorder combination

As they reach their teens, many with type 1 diabetes discover that the disease provides a secret weapon for losing weight. By restricting or reducing the amount of insulin they inject, they can eat just about anything they want and control their weight. [More]
New Tel Aviv University study reveals impact of skipping breakfast on the health of diabetics

New Tel Aviv University study reveals impact of skipping breakfast on the health of diabetics

More and more Americans on-the-go are skipping the "most important meal of the day," not eating until lunch. This tendency to miss breakfast has already been linked to the growing epidemic of obesity and cardiovascular problems in the US -- and it may put the health of diabetics at risk as well. [More]
Lilly Diabetes releases Android version of Glucagon Mobile App to support diabetes caregivers

Lilly Diabetes releases Android version of Glucagon Mobile App to support diabetes caregivers

Lilly Diabetes has released an Android version of its mobile application designed for caregivers and healthcare providers who support people with diabetes. Through an injection tutorial and emergency instructions, the App can help people practice the injection steps ahead of time, which may help them feel better prepared to assist. [More]
Study could provide paradigm shift in treatment of age-related disease, cancer

Study could provide paradigm shift in treatment of age-related disease, cancer

Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, including many chemotherapies. [More]
Advertisement